German court deals blow to Sanofi over cholesterol drug
05-06-2019
Fresenius files IPR against Amgen
15-04-2019
Sergiy Palamarchuk / Shutterstock.com
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, US Court of Appeals for the Federal Circuit, Fresenius, generics, Jevtana, cancer drugs, patent invalidity, big pharma
